July 29th 2025
Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.
Management of Young Breast Cancer Patients With de Novo Genetic Mutations
A 24-year-old woman presents to her primary care provider with a mass in her left breast. Examination confirms a 2.2-cm mass in the upper outer quadrant, with a single mobile axillary node that is firm to palpation.
CLEOPATRA: Pertuzumab Ups Survival by 16 Months in HER2-Positive Breast Cancer
September 30th 2014Data from the CLEOPATRA trial show that pertuzumab adds nearly 16 months to median survival times when used with trastuzumab and chemo in HER2-positive breast cancer, according to final results presented at the ESMO 2014 Congress.
Management of the Patient With Postpartum Breast Cancer
September 15th 2014Postpartum breast cancer represents a high-risk, under-recognized subset of young women’s breast cancer. The lack of clear identity for postpartum breast cancer is due in part to both the “dual effect” that pregnancy has on the incidence of breast cancer diagnosis.
Chemobrain: Is It Time to Initiate Guidelines for Assessment and Management?
September 15th 2014Cognitive dysfunction during and following treatment for cancer, often referred to as “chemobrain,” is an adverse effect of cancer treatment that may interfere with patients’ ability to resume their precancer lifestyle, with subsequently reduced quality of life.
Cancer- and Treatment-Related Cognitive Changes: What Can We Do Now? What Lies Ahead?
September 15th 2014Much of the existing research into the phenomenon commonly referred to as “chemobrain” has been descriptive, and we know enough now to identify some patients at risk for cognitive changes after a diagnosis of cancer.
Management of Breast Cancer Brain Metastases Is Moving Forward, but New Options Are Still Needed
July 15th 2014Prevention of CNS seeding early in the metastatic disease course using drugs with both intra- and extracranial activity will be crucial to improving outcomes in patients with breast cancer brain metastases.